FDA/Scottish Government deal raises members’ pay and protects jobs

Following union negotiations, FDA members working across the Scottish Government voted to accept the proposed 2019/2020 pay offer. This included a 3% consolidated pay rise for staff on the B3, C1, C2 and C3 scale maxima, and further non-consolidated payments for all staff on pay range maxima.
Meanwhile, staff below their pay range maximum will receive full progression to the next point of their pay scale.
The offer also featured a commitment to enforce no compulsory redundancies for the duration of the pay deal, and the introduction of a new rate of payment for staff required to be on call.
National Officer Allan Sampson said: “I am delighted that members have again voted to accept the pay offer for Scottish Government Main bargaining unit, securing for the second year in succession an above-inflation pay rise for our talented and hard-working members, and delivering upon ministers commitments to restoration of pay across the Scottish Sector.”
FDA Scottish Government Branch rep Jules Goodlet-Rowley, who worked alongside Sampson on the negotiations, believe the deal is “is the best that could have been achieved under the current conditions.” “Looking forward,” she said, “I am interested in how we continue the conversation with Scottish Government and our ministers to meet the expectations of our members while securing a fair deal for everyone”.
Related News
-
Under significant pressure: Interview with Director of Public Prosecutions
Tom Nathan speaks to Crown Prosecution Service Director of Public Prosecutions Stephen Parkinson about CPS’s handling of riots, the importance of impartiality and his plan to help reduce unmanageable prosecutor caseloads.
-
Changing the culture
HM Chief Inspector Sir Martyn Oliver sat down for an ‘in conversation’ event with FDA General Secretary Dave Penman, discussing the pace of change in Ofsted, challenging perceptions and tackling the long hours culture in Education.
-
Hybrid working: Led by evidence, not headlines
Tom Nathan shares the findings and recommendations of the FDA’s recent report on ‘The future of office working in the civil service’.